**Supplemental Digital Content 1 – Table listing the detailed histological subtypes and treatments performed for relapses**

|  |  |  |
| --- | --- | --- |
| TGCT | Detailed Histology | Treatment for Relapse |
| *TGCT #1* | EC + TE (mature + immature) | No relapse |
| *TGCT #2* | EC + YST + TE (mature) | 3xBEP |
| *TGCT #3* | SE + EC | No relapse |
| *TGCT #4* | SE + EC | 3xBEP |
| *TGCT #5* | EC + YST + TE | No relapse |
| *TGCT #6* | TE (mature) | No relapse |
| *TGCT #7* | EC + YST | No relapse |
| *TGCT #8* | EC + YST + TE | No relapse |
| *TGCT #9* | EC + YST + CH + TE (mature) | 3xBEP |
| *TGCT #10* | SE + EC | 2xBEP + 2xEP |
| *TGCT #11* | SE + EC + YST | 2xBEP + 2xEP |
| *TGCT #12* | SE + TE | No relapse |
| *TGCT #13* | SE + EC + YST + TE | 3xBEP + 1xEP |
| *TGCT #14* | SE + EC | No relapse |
| *TGCT #15* | EC | 3xVIP |
| *TGCT #16* | YST + TE (mature) | 3xBEP + RPLND |
| *TGCT #17* | EC + YST + TE | 4xBEP |
| *TGCT #18* | SE + EC | 2xBEP + 2xEP |
| *TGCT #19* | SE + EC + YST | No relapse |
| *TGCT #20* | SE + EC | 3xBEP |
| *TGCT #21* | EC + YST | 3xBEP |
| *TGCT #22* | EC + TE | 3xBEP |
| *TGCT #23* | SE + EC + YST | No relapse |
| *TGCT #24* | SE + EC | 3xBEP |
| *TGCT #25* | EC + YST + TE | 2xVIP |
| *TGCT #26* | SE + EC + YST + TE (mature and immature) | 3xCEB |
| *TGCT #27* | SE + EC | 3xBEP + 1xEP |
| *TGCT #28* | SE + EC + YST + CH + TE (mature) | No relapse |
| *TGCT #29* | EC + YST | 3xBEP |
| *TGCT #30* | SE + YST | No relapse |
| *TGCT #31* | EC + YST + TE | (RPLND) + (4xTIP+RPLND) |
| *TGCT #32* | SE + EC + YST | 3xBEP |
| *TGCT #33* | SE + EC + YST + TE (mature) | 3xBEP |
| *TGCT #34* | EC | No relapse |
| *TGCT #35* | EC | 3xBEP |
| *TGCT #36* | EC | 3xBEP + RPLND |
| *TGCT #37* | SE + EC + YST + TE | No relapse |
| *TGCT #38* | SE + EC + YST + TE | 3xBEP |
| *TGCT #39* | SE + EC | 3xBEP |
| *TGCT #40* | SE + EC + YST + TE (mature) | No relapse |
| *TGCT #41* | EC + YST | 3xBEP + 1xEP + RPLND |
| *TGCT #42* | EC + YST + TE (mature and immature) | No relapse |
| *TGCT #43* | SE + EC | RPLND + 3xBEP |
| *TGCT #44* | EC + YST + TE | 3xBEP |
| *TGCT #45* | EC + TE | No relapse |
| *TGCT #46* | EC + YST + TE (mature and immature) | (4xCEB) + (3xBOP+3xVIP-B) |
| *TGCT #47* | EC + YST + TE | No relapse |
| *TGCT #48* | EC | 4xBEP |
| *TGCT #49* | TE (mature) | No relapse |
| *TGCT #50* | EC + YST + CH + TE | No relapse |
| *TGCT #51* | EC + YST + TE (mature and immature) | 3xBEP |
| *TGCT #52* | SE + EC + YST + TE (mature and immature) | No relapse |

**Abbreviations:** BEP – bleomycin, etoposide, cisplatin; BOP – bleomycin, vincristine, cisplatin; CEB - bleomycin, etoposide, carboplatin; CH – choriocarcinoma; EC – embryonal carcinoma; EP – etoposide, cisplatin; RPLND – retroperitoneal lymph-node disease; SE – seminoma; TE – teratoma; TGCT – testicular germ cell tumor; TIP – paclitaxel, ifosfamide, cisplatin; VIP – etoposide, ifosfamide, cisplatin; VIP-B - etoposide, ifosfamide, cisplatin, bleomycin; YST – yolk sac tumor

Legend: **Supplemental Digital Content 1. Table listing the detailed histological subtypes and treatments performed for relapses** *(Word file, docx)*.